Evolution AB (publ) (EVO) Q3 Rev €526.1M, EBITDA €345.9M; Brazil Studio Shut

Evolution AB reported Q3 2026 revenue of €526.1M, up 3.7% YoY, and adjusted EBITDA of €345.9M (65.8% margin). The company temporarily closed its Brazilian studio due to regulatory changes, with Brazil contributing less than half of LatAm revenues.

Original reporting
Published Oct 23, 2026, 5:30 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 23, 2026, 5:37 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Evolution AB (publ) (EVO) Q3 Rev €526.1M, EBITDA €345.9M; Brazil Studio Shut — source image
Decision brief

The 30-second read

$EVONeutralMed
01

Why it matters

The earnings numbers are modestly positive on margins but the Brazil setback introduces risk, likely resulting in a muted market reaction.

02

Market read

Primary earnings disclosure for a mid‑cap gaming company; relevance is moderate for traders tracking European gaming stocks.

03

What to watch

The temporary Brazil studio closure may be short‑term; long‑term growth could resume if regulations ease.

Relevance 6/10Novelty 7/10Timing: post-market today

Background

Evolution AB is a European gaming company listed on Nasdaq under the ticker EVO. The Q3 release provides the latest financial snapshot and notes a regulatory issue in Brazil.

Company-level read

Ticker impact

$EVONeutralMedium confidence
Context

Evolution AB reported Q3 2026 revenue of €526.1M and adjusted EBITDA of €345.9M, its first public disclosure of these figures.

Expected impact

potential slight pressure as investors weigh modest growth against high margin expectations

Evidence & confidence

The earnings beat is limited to margin strength; revenue growth of 3.7% YoY is modest, and the Brazil studio shutdown adds uncertainty.

Market effects

Highlights challenges in the Latin American gaming market and may prompt peers to reassess regional exposure.

Brazil regulatory rollback could affect other gaming firms operating in the region.

Limited to the niche gaming sector; broader market impact is minimal.

Counterpoint

Investors could view the strong EBITDA margin as a sign of operational efficiency and buy on dip.

Key entities

  • Evolution AB

    European gaming firm listed on Nasdaq (EVO).

Related articles

$EVOMedAI 8/10

Evotec secures second FDA clearance under BMS partnership

Evotec SE said the FDA accepted a second IND for a CELMoD molecular glue degrader under its partnership with Bristol Myers Squibb. Evotec expects Phase 1 in 2027, after the first candidate entered Phase 1 in March 2026 for advanced clear cell renal cell carcinoma.

$EVOMedAI 8/10

Evotec and Bristol Myers Squibb Advance Strategic Protein Degradation Partnership with Second IND Acceptance

Evotec (EVO) and Bristol Myers Squibb received FDA clearance for a second Investigational New Drug (IND) in their protein degradation partnership. The first candidate entered Phase 1 trials in March 2026, and the second is expected to start in 2027. The collaboration leverages Evotec's drug discovery capabilities and Bristol Myers Squibb's CELMoD agent library to develop molecular glue degraders for oncology and other therapeutic areas.

$EVOMed

What Evotec (EVO) Said on Its Q3 Earnings Call

Evotec (EVO) expects Q4 revenue and profitability to decline due to lower milestone contributions. Net sales in D&PD base business rose 24% YoY in the first nine months. The company plans a manufacturing expansion in 2027 and has achieved 20% of its €75M annual savings target. Evotec reiterated its 2030 revenue goal of €1B and a 20% EBITDA margin by 2030.

Med

Evotec SE (EVO): Financial results for H2 2026

Evotec SE (EVO) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 For further information, please contact : Dr. Sarah Fakih, EVP Head of Global Communications and Investor Relations, sarah.fakih@evotec.com, M. +49.(0)151 70 688 784, www.evotec.com INTERIM STATEMENT 9M 2026 HIGHLIGHTS 4 D&PD LEADING COMMERCIAL INDICATORS SHOW CONTIN